{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:28:48Z","timestamp":1793413728927,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12015-026-11137-1","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:15:27Z","timestamp":1778469327000},"page":"2612-2621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bone Marrow Mesenchymal Stem Cell Extracellular Vesicle Treatment of Respiratory Failure from COVID-19: Endpoint Analysis of Expanded Access Safety Trial"],"prefix":"10.1007","volume":"22","author":[{"given":"Vikram","family":"Sengupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Ransom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy I.","family":"Melson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Awili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack M.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-6610","authenticated-orcid":false,"given":"Timothy A.","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"1","key":"11137_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13054-020-02911-9","volume":"24","author":"X Li","year":"2020","unstructured":"Li, X., & Ma, X. (2020). Acute respiratory failure in COVID-19: is it typical ARDS? Critical care (London England), 24(1), 198.","journal-title":"Critical care (London England)"},{"issue":"8","key":"11137_CR2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(20)30304-0","volume":"8","author":"E Fan","year":"2020","unstructured":"Fan, E., Beitler, J. R., Brochard, L., et al. (2020). COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med, 8(8), 816\u2013821.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"11137_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jointm.2023.02.003","volume":"3","author":"FM Beloncle","year":"2023","unstructured":"Beloncle, F. M. (2023). Is COVID-19 different from other causes of acute respiratory distress syndrome? J Intensive Med, 3(3), 212\u2013219.","journal-title":"J Intensive Med"},{"issue":"1","key":"11137_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s13054-020-03253-2","volume":"24","author":"DL Grieco","year":"2020","unstructured":"Grieco, D. L., Bongiovanni, F., Chen, L., et al. (2020). Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies. Critical care (London England), 24(1), 529.","journal-title":"Critical care (London England)"},{"issue":"24","key":"11137_CR5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2020.8907","volume":"323","author":"T Schaller","year":"2020","unstructured":"Schaller, T., Hirschb\u00fchl, K., Burkhardt, K., et al. (2020). Postmortem Examination of Patients With COVID-19. Jama, 323(24), 2518\u20132520.","journal-title":"Jama"},{"issue":"6","key":"11137_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41379-020-0536-x","volume":"33","author":"S Tian","year":"2020","unstructured":"Tian, S., Xiong, Y., Liu, H., et al. (2020). Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern pathology: an official journal of the United States and Canadian Academy of Pathology Inc, 33(6), 1007\u20131014.","journal-title":"Modern pathology: an official journal of the United States and Canadian Academy of Pathology Inc"},{"issue":"1","key":"11137_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13054-022-04287-4","volume":"27","author":"F Wang","year":"2023","unstructured":"Wang, F., Li, Y., Wang, B., Li, J., & Peng, Z. (2023). The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Critical care (London England), 27(1), 31.","journal-title":"Critical care (London England)"},{"issue":"1","key":"11137_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00134-021-06570-4","volume":"48","author":"G Bellingan","year":"2022","unstructured":"Bellingan, G., Jacono, F., Bannard-Smith, J., et al. (2022). Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial. Intensive care medicine, 48(1), 36\u201344.","journal-title":"Intensive care medicine"},{"issue":"3","key":"11137_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","volume":"207","author":"ME Bowdish","year":"2023","unstructured":"Bowdish, M. E., Barkauskas, C. E., Overbey, J. R., et al. (2023). A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19. American journal of respiratory and critical care medicine, 207(3), 261\u2013270.","journal-title":"American journal of respiratory and critical care medicine"},{"key":"11137_CR10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202302-0297OC","author":"EA Gorman","year":"2023","unstructured":"Gorman, E. A., Rynne, J., Gardiner, H. J., et al. (2023). Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID Trial): A multicentre, randomised, controlled trial. American Journal of Respiratory and Critical Care Medicine. https:\/\/doi.org\/10.1164\/rccm.202302-0297OC","journal-title":"American journal of respiratory and critical care medicine"},{"key":"11137_CR11","doi-asserted-by":"crossref","unstructured":"Calzetta, L., Aiello, M., Frizzelli, A. (2022). Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. Cells 11(11).","DOI":"10.3390\/cells11111797"},{"issue":"13","key":"11137_CR12","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.7150\/ijms.59218","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen, X., Wang, F., Huang, Z., Wu, Y., Geng, J., & Wang, Y. (2021). Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review. International Journal Of Medical Sciences, 18(13), 2849\u20132870.","journal-title":"International Journal Of Medical Sciences"},{"issue":"1","key":"11137_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13287-022-02956-3","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang, J., Luo, F., Suo, Y., et al. (2022). Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs. Stem Cell Research & Therapy, 13(1), 275.","journal-title":"Stem cell research & therapy"},{"issue":"9","key":"11137_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1538-7836.2008.03077.x","volume":"6","author":"A Gonsalves","year":"2008","unstructured":"Gonsalves, A., Carrier, M., Wells, P. S., Mcdiarmid, S. A., Huebsch, L. B., & Allan, D. S. (2008). Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. Journal Of Thrombosis And Haemostasis, 6(9), 1468\u20131473.","journal-title":"Journal Of Thrombosis And Haemostasis"},{"key":"11137_CR15","doi-asserted-by":"publisher","unstructured":"Guo, M., Qi, J., Hou, Q., Li, X., & Han, Y. (2023). Risk factors for transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis. Expert Review of Hematology, 1\u201313. https:\/\/doi.org\/10.1080\/17474086.2023.2162501","DOI":"10.1080\/17474086.2023.2162501"},{"issue":"9","key":"11137_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00277-016-2673-3","volume":"95","author":"MF Zahid","year":"2016","unstructured":"Zahid, M. F., Murad, M. H., Litzow, M. R., et al. (2016). Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Annals Of Hematology, 95(9), 1457\u20131464.","journal-title":"Annals Of Hematology"},{"key":"11137_CR17","first-page":"608","volume":"5","author":"OG De Jong","year":"2014","unstructured":"De Jong, O. G., Van Balkom, B. W., Schiffelers, R. M., Bouten, C. V., & Verhaar, M. C. (2014). Extracellular vesicles: potential roles in regenerative medicine. Frontiers in Immunology, 5, 608.","journal-title":"Frontiers in immunology"},{"issue":"1","key":"11137_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13287-021-02143-w","volume":"12","author":"H Kaspi","year":"2021","unstructured":"Kaspi, H., Semo, J., Abramov, N., et al. (2021). MSC-NTF (NurOwn\u00ae) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model. Stem Cell Research & Therapy, 12(1), 72.","journal-title":"Stem cell research & therapy"},{"key":"11137_CR19","doi-asserted-by":"publisher","unstructured":"Krishnan, A., Muthusamy, S., Fernandez, F. B., & Kasoju, N. (2022). Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Management of COVID19-Associated Lung Injury: A Review on Publications, Clinical Trials and Patent Landscape. Tissue Engineering and Regenerative Medicine, (1\u201315). https:\/\/doi.org\/10.1007\/s13770-022-00441-9","DOI":"10.1007\/s13770-022-00441-9"},{"issue":"1","key":"11137_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13287-021-02138-7","volume":"12","author":"Y Tang","year":"2021","unstructured":"Tang, Y., Zhou, Y., & Li, H. J. (2021). Advances in mesenchymal stem cell exosomes: a review. Stem cell Research & Therapy, 12(1), 71.","journal-title":"Stem cell research & therapy"},{"key":"11137_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.06.024","author":"AL Lightner","year":"2023","unstructured":"Lightner, A. L., Sengupta, V., Qian, S., et al. (2023). Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure from COVID-19: A Randomized Placebo Controlled Dosing Clinical Trial. Chest. https:\/\/doi.org\/10.1016\/j.chest.2023.06.024","journal-title":"Chest"},{"issue":"12","key":"11137_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1089\/scd.2020.0080","volume":"29","author":"V Sengupta","year":"2020","unstructured":"Sengupta, V., Sengupta, S., Lazo, A., Woods, P., Nolan, A., & Bremer, N. (2020). Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells and Development, 29(12), 747\u2013754.","journal-title":"Stem cells and development"},{"issue":"19","key":"11137_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H., Tomashek, K. M., Dodd, L. E., et al. (2020). Remdesivir for the Treatment of Covid-19 - Final Report. New England Journal Of Medicine, 383(19), 1813\u20131826.","journal-title":"New England Journal Of Medicine"},{"issue":"8","key":"11137_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby, P., Lim, W. S., Emberson, J. R., et al. (2021). Dexamethasone in Hospitalized Patients with Covid-19. New England Journal Of Medicine, 384(8), 693\u2013704.","journal-title":"New England Journal Of Medicine"},{"issue":"10285","key":"11137_CR25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RC Group","year":"2021","unstructured":"Group, R. C. (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10285), 1637\u20131645.","journal-title":"Lancet"},{"issue":"7","key":"11137_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2201662","volume":"387","author":"CT Bramante","year":"2022","unstructured":"Bramante, C. T., Huling, J. D., Tignanelli, C. J., et al. (2022). Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. New England Journal Of Medicine, 387(7), 599\u2013610.","journal-title":"New England Journal Of Medicine"},{"issue":"18","key":"11137_CR27","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","volume":"386","author":"G Reis","year":"2022","unstructured":"Reis, G., Silva, E., Silva, D. C. M., et al. (2022). Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal Of Medicine, 386(18), 1721\u20131731.","journal-title":"New England Journal Of Medicine"},{"issue":"12","key":"11137_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1080\/14740338.2022.2160446","volume":"21","author":"G Casalini","year":"2022","unstructured":"Casalini, G., Giacomelli, A., & Antinori, S. (2022). Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. Expert Opinion on Drug Safety, 21(12), 1483\u20131494.","journal-title":"Expert Opin Drug Saf"},{"key":"11137_CR29","doi-asserted-by":"publisher","first-page":"114800","DOI":"10.1016\/j.bcp.2021.114800","volume":"193","author":"E De Clercq","year":"2021","unstructured":"De Clercq, E. (2021). Remdesivir: Quo vadis? Biochemical Pharmacology, 193, 114800.","journal-title":"Biochemical pharmacology"},{"issue":"1","key":"11137_CR30","first-page":"Cd014962","volume":"1","author":"F Grundeis","year":"2023","unstructured":"Grundeis, F., Ansems, K., Dahms, K., et al. (2023). Remdesivir for the treatment of COVID-19. The Cochrane Database of Systematic Reviews, 1(1), Cd014962.","journal-title":"The Cochrane database of systematic reviews"},{"key":"11137_CR31","doi-asserted-by":"publisher","unstructured":"Hsu, J. Y., Mao, Y. C., Liu, P. Y., & Lai, K. L. (2021). Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. Pharmaceuticals (Basel Switzerland) 14(10). https:\/\/doi.org\/10.3390\/ph14100955","DOI":"10.3390\/ph14100955"},{"issue":"1","key":"11137_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40121-022-00729-2","volume":"12","author":"G Tiseo","year":"2023","unstructured":"Tiseo, G., Barbieri, C., Galfo, V., et al. (2023). Efficacy and safety of nirmatrelvir\/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: The PISA outpatient clinic experience. Infectious Diseases and Therapy, 12(1), 257\u2013271.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"11137_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/cbin.10742","volume":"41","author":"B Derkus","year":"2017","unstructured":"Derkus, B., Emregul, K. C., & Emregul, E. (2017). A new approach in stem cell research-Exosomes: Their mechanism of action via cellular pathways. Cell Biology International, 41(5), 466\u2013475.","journal-title":"Cell Biology International"},{"issue":"6","key":"11137_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/stem.643","volume":"29","author":"JW Lee","year":"2011","unstructured":"Lee, J. W., Fang, X., Krasnodembskaya, A., Howard, J. P., & Matthay, M. A. (2011). Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells, 29(6), 913\u2013919.","journal-title":"Stem Cells"},{"issue":"3","key":"11137_CR35","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.3390\/ijms15034142","volume":"15","author":"B Yu","year":"2014","unstructured":"Yu, B., Zhang, X., & Li, X. (2014). Exosomes derived from mesenchymal stem cells. International Journal of Molecular Sciences, 15(3), 4142\u20134157.","journal-title":"International journal of molecular sciences"},{"issue":"1","key":"11137_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1164\/rccm.201503-0584OC","volume":"193","author":"ED Riviello","year":"2016","unstructured":"Riviello, E. D., Kiviri, W., Twagirumugabe, T., et al. (2016). Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. American Journal of Respiratory and Critical Care Medicine, 193(1), 52\u201359.","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"14","key":"11137_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/scd.2020.0095","volume":"29","author":"V Sengupta","year":"2020","unstructured":"Sengupta, V., Sengupta, S., Lazo, A., Hicok, K. C. Jr., & Moseley, T. (2020). Response to, Lim, et al. re: Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells and Development, 29(14), 879\u2013881.","journal-title":"Stem Cells and Development"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11137-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11137-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11137-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:32:01Z","timestamp":1780662721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11137-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["11137"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11137-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8890163\/v1","asserted-by":"object"}]},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol was approved by the institutional review board (IRB) at each site (or a centralized IRB as applicable) and overseen by a data and safety monitoring board (DSMB) that was fully independent of both study sponsor and director.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent (or consent by other IRB-approved process) was obtained from each patient, or patient\u2019s legally authorized representative if the patient was unable to provide consent, following a discussion of informed consent principles with the investigator.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consent for publication is contained within the informed consent form and permission is granted upon signing the consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Vikram Sengupta: prior CMO at Direct Biologics, Sascha Qian: prior Associate CMO at Direct Biologics, John T. Ransom: Sr. Medical Writer at Direct Biologics, Timothy A. Moseley: CSO at Direct Biologics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}